Effect of Antipsychotic Medications on Glucose and Lipid Levels
Abstract
Severe mental illnesses, such as schizophrenia and bipolar affective disorder, are associated with excess cardiovascular morbidity and mortality. Cardiovascular risk in psychiatric disorders is partly related to antipsychotic therapy, especially second-generation or atypical antipsychotics. Some antipsychotic medications are associated with proatherogenic conditions including insulin resistance and dyslipidemia. In particular, olanzapine and clozapine have been consistently demonstrated to promote insulin resistance and dyslipidemia. Ziprasidone and amisulpiride may be associated with more favorable metabolic effects. Many of the published data relating to metabolic effects of anti-psychotics originate from retrospective studies. However, prospective randomized-controlled data are emerging, and the latest evidence is described here.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Ziprasidone probably improves lipid levels.
“Comparative research revealed that haloperidol and quetiapine can increase lipid levels; ziprasidone probably improves lipid levels, while risperidone can produce both effects [133].”
From Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers (2024) · cites this paper as [133]
The citation lists haven’t been fetched yet
References 32 · Cited by 65
- Authors
- Chaggar, P. S., Shaw, S. M., & Williams, S. G.
- Affiliations
- Essex Cardiothoracic Centre (GB)
- Wythenshawe Hospital (GB)
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2011-05
- Volume
- 51
- Issue
- 5
- Pages
- 631-638
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- OpenAlex
- W2064520145
- Cited by
- 65
- References
- 32
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 4 · 2021: 2 · 2020: 4 · 2019: 6 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 3 · 2013: 8 · 2012: 8
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- antipsychotic drugs, metabolic side effects, insulin resistance, dyslipidemia, glucose metabolism, cardiovascular risk, schizophrenia, bipolar disorder, atypical antipsychotics, olanzapine, clozapine, ziprasidone, atherogenic risk
- MeSH terms
- Blood Glucose, Cardiovascular Diseases, Humans, Insulin Resistance, Lipids, Risk Factors, Antipsychotic Agents, Risk Assessment, Evidence-Based Medicine, Glucose Metabolism Disorders, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
